What question did this study set out to answer?

Establish simple, reliable, and standardized consensus criteria for diagnosing and classifying monoclonal gammopathies and multiple myeloma using routinely available clinical tests.

May 28, 2003British Journal of HaematologyOpen Access

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

View Full Paper

Ask AI

Bookmark

Discussion

Member takes

Overview

Consensus review reports standardized diagnostic criteria in monoclonal gammopathy and myeloma, facilitating therapeutic trial comparisons.

Key Points

Establish simple, reliable, and standardized consensus criteria for diagnosing and classifying monoclonal gammopathies and multiple myeloma using routinely available clinical tests.
Convened the International Myeloma Working Group to review diagnostic criteria and classification systems for plasma cell proliferative disorders.
Defined disease categories based on routine laboratory tests measuring monoclonal protein levels, bone marrow clonal plasma cell percentages, and clinical signs of end-organ impairment.
Monoclonal gammopathy of undetermined significance (MGUS) is classified by serum monoclonal protein < 30 g/l, bone marrow clonal cells < 10%, and no evidence of multiple myeloma, other B-cell disorders, or amyloidosis.
Asymptomatic (smouldering) myeloma is characterized by monoclonal protein ≥ 30 g/l and/or bone marrow clonal cells ≥ 10% without related organ or tissue impairment (ROTI).
Symptomatic myeloma requires demonstrated ROTI (hypercalcemia, renal insufficiency, anemia, or bone lesions), with distinct definitions also established for non-secretory myeloma and solitary plasmacytomas.

Cite This Study

A 2003 study studied this question.

synapsesocial.com/papers/6a7d324d00c5c9efbcaa113d https://doi.org/10.1046/j.1365-2141.2003.04355.x

View Full Paper

Ask AI

Bookmark

May 28, 2003British Journal of HaematologyOpen Access

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

View Full Paper

Ask AI

Bookmark

Discussion

Member takes

Overview

Consensus review reports standardized diagnostic criteria in monoclonal gammopathy and myeloma, facilitating therapeutic trial comparisons.

Key Points

Establish simple, reliable, and standardized consensus criteria for diagnosing and classifying monoclonal gammopathies and multiple myeloma using routinely available clinical tests.
Convened the International Myeloma Working Group to review diagnostic criteria and classification systems for plasma cell proliferative disorders.
Defined disease categories based on routine laboratory tests measuring monoclonal protein levels, bone marrow clonal plasma cell percentages, and clinical signs of end-organ impairment.
Monoclonal gammopathy of undetermined significance (MGUS) is classified by serum monoclonal protein < 30 g/l, bone marrow clonal cells < 10%, and no evidence of multiple myeloma, other B-cell disorders, or amyloidosis.
Asymptomatic (smouldering) myeloma is characterized by monoclonal protein ≥ 30 g/l and/or bone marrow clonal cells ≥ 10% without related organ or tissue impairment (ROTI).
Symptomatic myeloma requires demonstrated ROTI (hypercalcemia, renal insufficiency, anemia, or bone lesions), with distinct definitions also established for non-secretory myeloma and solitary plasmacytomas.

Cite This Study

A 2003 study studied this question.

synapsesocial.com/papers/6a7d324d00c5c9efbcaa113d https://doi.org/10.1046/j.1365-2141.2003.04355.x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark